Health Care • Biotechnology: Pharmaceutical Preparations
$431.70 ▲ +0.70
(+0.16%)
MKT CAP: $9.97B • VOL: 268.0K
52W L $399 52W H $615
MDGL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $958.4M | $180.1M | $0 |
| YoY Revenue Growth % | +432.1% | — | — |
| Gross Profit | $421.7M | $173.9M | $0 |
| Gross Margin % | 44.0% | 96.5% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$300.1M | -$497.9M | -$380.5M |
| Operating Margin % | -31.3% | -276.4% | — |
| Net Income (GAAP) | -$288.3M | -$465.9M | -$373.6M |
| EBITDA (Normalized) | -$299.7M | -$496.7M | -$380.5M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$189.6M | -$455.6M | -$324.2M |
| Capital Expenditures (CapEx) | $467.0K | $1.5M | $0 |
| Free Cash Flow (FCF) | -$190.0M | -$457.0M | -$324.2M |
| FCF Margin % | -19.8% | -253.7% | — |
| Return on Invested Capital (ROIC %) | -31.9% | -45.0% | -9.1% |
| Cash & Short-Term Equivalents | $198.7M | $100.0M | $603.4M |
| Total Debt (Short + Long Term) | $339.9M | $117.6M | $1.28B |
| Total Stockholders' Equity | $602.7M | $754.4M | $2.63B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MDGL.